Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q14679
UPID:
TTLL4_HUMAN
Alternative names:
Protein monoglutamylase TTLL4; Tubulin--tyrosine ligase-like protein 4
Alternative UPACC:
Q14679; A8K6V5; Q8WW29
Background:
Tubulin monoglutamylase TTLL4, also known as Protein monoglutamylase TTLL4 and Tubulin--tyrosine ligase-like protein 4, plays a crucial role in cellular functions by modifying tubulin and non-tubulin proteins. It adds a single glutamate to specific residues, influencing processes like nucleosome assembly and antiviral defense by modifying proteins such as NAP1L1, NAP1L4, and CGAS. Its preference for beta-tail tubulin over alpha-tubulin highlights its specificity in protein modification.
Therapeutic significance:
Understanding the role of Tubulin monoglutamylase TTLL4 could open doors to potential therapeutic strategies, particularly in manipulating its activity to influence cell reprogramming, pluripotency maintenance, and embryogenesis.